Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains
Autore:
Houben, MHMG; Hensen, EF; Rauws, EAJ; Van der Hulst, RWM; Vant Hoff, BWM; Van der Ende, A; Ten Kate, FJW; Tytgat, GNJ;
Indirizzi:
Red Cross Hosp, Dept Internal Med, NL-2566 MJ The Hague, Netherlands Red Cross Hosp The Hague Netherlands NL-2566 MJ J The Hague, Netherlands Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, NL-1105 AZ Amsterdam, Netherlands Univ Amsterdam Amsterdam Netherlands NL-1105 AZ Z Amsterdam, Netherlands Univ Amsterdam, Acad Med Ctr, Dept Clin Microbiol, NL-1105 AZ Amsterdam, Netherlands Univ Amsterdam Amsterdam Netherlands NL-1105 AZ Z Amsterdam, Netherlands Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands Univ Amsterdam Amsterdam Netherlands NL-1105 AZ Z Amsterdam, Netherlands
Titolo Testata:
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
fascicolo: 7, volume: 13, anno: 1999,
pagine: 883 - 889
SICI:
0269-2813(199907)13:7<883:RTOOAC>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
PEPTIC-ULCER DISEASE; WEEK TRIPLE THERAPY; IN-VITRO; ERADICATION; INFECTION; AMOXICILLIN; GASTRITIS; RELEVANCE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Houben, MHMG Red Cross Hosp, Dept Internal Med, Sportlaan 600, NL-2566 MJ The Hague, Netherlands Red Cross Hosp Sportlaan 600 The Hague Netherlands NL-2566 MJ
Citazione:
M.H.M.G. Houben et al., "Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains", ALIM PHARM, 13(7), 1999, pp. 883-889

Abstract

Background: The impact of metronidazole resistance on the efficacy of proton pump inhibitor based triple therapies remains unclear. Aim: To study whether metronidazole resistance affects Helicobacter pylorieradication rates in patients treated for 1 week. with either omeprazole 20 mg b.d., metronidazole 400 mg b.d. and clarithromycin 350 mg b.d. (OMC), or omeprazole 20 mg b.d., amoxycillin 1000 mg b.d. and clarithromycin 500 mg b.d. (OAC). Methods: A randomized, single blind, single centre study with parallel groups was conducted. H. pylori positive patients were enrolled in a metronidazole-resistant (MR: MIC > 8 mu g/mL) or a metronidazole-susceptible group (MS; MIC < 4 mu g/mL), as determined by E-test, Within the strata patients were randomized to either OAC or OMC. Results: One hundred and twenty-two patients were included. The per protocol cure rate for OAC was 52 out of 57 (91%) (MS 23 out of 26 (89%); MR 29 out of 31 (94%)) and for OMC 46 out of 55 (84%) (MS 19 out of 22 (86%): MR 27 out of 33 (82%)). Conclusions: One-week OAC and OMC are effective therapies, OAC and OMC were equally effective in patients with metronidazole-susceptible strains of H. pylori. Using the OMC regimen, neither equality nor significant differences in treatment outcome could be shown between patients with metronidazole-resistant or -susceptible strains of H. pylori.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 08:22:08